BioSpace News Archive

BlueRock Therapeutics LP announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD).

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the acquisition of Tissue Solutions Ltd., a virtual biobank based in Glasgow, UK.

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for RLS102.

Imbria Pharmaceuticals today announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase 2 study

Allegro Ophthalmics , LLC today announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting being held July 23-27 in Las Vegas, NV.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCE TM.

Masimo Introduces the MX-7™ rainbow SET ® Technology Board for Original Equipment Manufacturing Partners

INmune Bio, Inc. announced today that the Company will present a poster at the Alzheimer’s Association International Congress 2021.

Neurana Pharmaceuticals, Inc. today announced participation at the SVB Leerink Biopharma Private Company Connect. The conference takes place virtually July 21st -22 nd.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a distribution agreement with Fosun Pharma for the cPass™ SARS-CoV-2 Neutralizing Antibody Detection Kit* that has received Emergency Use Authorization (“EUA”) from the US FDA for the detection of SARS-CoV-2 receptor binding domain (“RBD” or “neutralizing”) antibodies.